

Advised BioCryst Pharmaceuticals on \$400 Million Debt Financing for Acquisition of Astria Therapeutics

Firm News | February 4, 2026

Gibson Dunn represented BioCryst Pharmaceuticals, Inc. in connection with a \$400 million senior secured term loan facility to finance the acquisition of Astria Therapeutics, Inc. The Gibson Dunn finance team involved in the transaction was led by partner Jin Hee Kim and included associates Paul Rafla, Jaclyn Wang, Aliya Zuberi, and Ruqi Wei. Partners Ryan Murr, Karen Spindler, and Meghan Hungate advised on licensing and intellectual property. Of counsel Carlo Felizardo and associate Michael Dziuban advised on FDA and regulatory matters. Partner Matt Donnelly, of counsel Kate Long, and associate Jason Zhang advised on tax aspects.

Related People

[Jin Hee Kim](#)

[Paul Rafla](#)

[Jaclyn Wang](#)

[Aliya Zuberi](#)

[Ruqi Wei](#)

[Ryan A. Murr](#)

[Karen A. Spindler](#)

[Meghan M. Hungate](#)

[Carlo Felizardo](#)

[Michael R. Dziuban](#)

[Matt Donnelly](#)

[Kate Long](#)

Related Capabilities

[Finance](#)

[Intellectual Property](#)

[Life Sciences](#)

[FDA and Health Care](#)

[Tax](#)